Published: Feb 16, 2017 8:16 a.m. ET By <strong>Pfizer Inc</strong>. PFE, -0.21% said early Thursday that its Xeljanz drug met its primary endpoint in combination with methotrexate as compared to <strong>AbbVie</strong>'s ABBV, -0.08% blockbuster drug Humira, although it didn't meet the primary endpoint on its own. The results of the phase 3B/4 trial, which lasted 12 months and enrolled about 1,150 patients, show Xeljanz's efficacy as a combination therapy for moderate-to-severe rheumatoid arthritis, said Chief Development Officer Michael Corbo. Xeljanz has already been approved for rheumatoid arthritis in the U.S., but pharmaceutical companies have increasingly looked to efficacy data to show the value of their treatments relative to competitors'. Humira is the world's top-selling drug. <strong>Pfizer</strong> shares have risen 4.9% over the last three months, compared with a 7.9% rise in the S P 500 SPX, -0.24% Copyright 2017 MarketWatch, Inc. All rights reserved. By using this site you agree to the Terms of Service , Privacy Policy , and Cookie Policy . Intraday Data provided by SIX Financial Information and subject to terms of use . Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S P/Dow Jones Indices (SM) from Dow Jones Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.


